Production (Stage)
Mineralys Therapeutics, Inc.
MLYS
$16.12
$0.503.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.97% | -100.69% | -147.55% | -237.81% | -149.90% |
| Total Depreciation and Amortization | 87.50% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 917.30% | 395.07% | 211.20% | 103.54% | -200.00% |
| Change in Net Operating Assets | -146.45% | -394.83% | 39.02% | 243.71% | 20,885.25% |
| Cash from Operations | -137.67% | -130.64% | -163.71% | -47.88% | -49.82% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -66.17% | 1,133.13% | 1,887.57% | 147.93% | 60.15% |
| Cash from Investing | -65.99% | 1,133.13% | 1,886.65% | 147.93% | 60.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 62.80% | 85.14% | -78.26% | -- | -42.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 84.13% | -- | -- | -- | -- |
| Cash from Financing | 62.88% | 21.62% | -100.54% | 73.84% | -42.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 23.84% | 145.46% | 298.23% | 39.20% | -18.66% |